Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
Category: #health  By Mateen Dalal  Date: 2019-09-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
  • Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) will be treated by Oncopeptides AB.
  • In the company’s HORIZON trial, a cumulative response rate of 23% was attained with dexamethasone and melflfufen in RRMM patients suffering from EMD.

Oncopeptides AB, a pharmaceutical company established in 2000 aimed at developing drugs to treat cancer, reportedly announced interim safety and efficacy data update from the ongoing Phase 2 HORIZON trial during 17th International Myeloma Workshop (IMW) being conducted at Boston, Massachusetts, USA.  

The outcomes presented during IMW 2019 by Prof. Paul G Richardson during the plenary session “Late Breaking Abstracts” with title name: Activity of Melflufen in RRMM Patients with EMD(Extramedullary Disease) in Phase 2 Study (OP-106 HORIZON) – promising outcomes in a high-risk population, are further based on a data cur from the company’s HORIZON trial conducted in July of 2019 when 136 participants were treated in comparison to earlier reported data which included 121 patients.

HORIZON represents the biggest clinical cohort based on literature till date of patients having myeloma that are diagnosed with extra medullary disease (EMD).

Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) is a population that is highly difficult to treat. In very recent single-agent trial (without or with steroids) comprising RRMM patients having EMD have demonstrated overall response rates (ORR) falling between 0 – 17%.

Only daratumumab has been able to show any relavant clinical activity having an overall response rate of 17% in patients with daratumumab naïve myeloma with EMD.

In the HORIZON trial, an ORR (overall response rate) of 23% was achieved when treated with dexamethasone and melflfufen in RRMM patients suffering from EMD. Mainly, penta refractory patients were found under this category (who have undergone five prior treatments at least and were resistant to a minimum of one proteasome inhibitor, one anti-CD38 and IMiD treatment).

Source credit: https://www.oncopeptides.se/en/new-interim-data-in-rrmm-patients-with-extramedullary-disease-from-the-pivotal-phase-2-horizon-study-presented-at-international-myeloma-workshop/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...